Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03589547

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung — 358  

Stage III Non-small-cell Lung Cancer Clinical Trial

Official title:
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Clinical Trial Summary

Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation. With SBRT, radiation is focused toward the cancer and away from normal surrounding lung tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more effective in activating the immune system. SBRT is a standard FDA approved treatment for early stage (stage 1) lung cancer and is investigational in patients such as yourself with stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03589547
Study type Interventional
Source Brown University
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 13, 2019
Completion date October 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04085250 - Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Completed NCT01733589 - Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC Phase 1/Phase 2
Recruiting NCT04325763 - A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) Phase 3
Not yet recruiting NCT04304638 - Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Active, not recruiting NCT01576796 - Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer Phase 2
Recruiting NCT04441138 - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC Phase 2
Not yet recruiting NCT04181372 - A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer Phase 2
Terminated NCT03871153 - Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer Phase 2
Completed NCT05331833 - Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.